Placebo + Cisapride

ApprovedTerminated

0 views this week 0 watching💤 Quiet

Interest: 35/100

Hype Score

Development Stage

✓

Pre-clinical

✓

Phase 1

✓

Phase 2

✓

Phase 3

Approved

Indication / Disease

Infant, Premature

Conditions

Infant, Premature, Infant, Newborn

Trial Timeline

Mar 1, 2003 → Jul 1, 2003

NCT ID

NCT01281566

About Placebo + Cisapride

Placebo + Cisapride is a approved stage product being developed by Johnson & Johnson for Infant, Premature. The current trial status is terminated. This product is registered under clinical trial identifier NCT01281566. Target conditions include Infant, Premature, Infant, Newborn.

What happened to similar drugs?

3 of 13 similar drugs in Infant, Premature were approved

Approved (3) Terminated (3) Active (9)

✅alglucosidase alfa + alglucosidase alfaSanofiApproved

✅Bacillus Clausii Multi ATB Resist + PlaceboSanofiApproved

✅VigabatrinLundbeckApproved

🔄somatropinEli LillyPhase 3

🔄RotaTeq (V260) + IPVMerckPhase 3

❌Recombinant human growth hormone (r-hGH)MerckPhase 3

🔄Genotropin (PN-180,307) Somatropin + Control-no treatmentPfizerPhase 3

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (2)

NCT ID	Phase	Status	Start	Completion	Indication
NCT01281553	Approved	Terminated	Sep 1, 2003	Oct 1, 2003	Gastroesophageal Reflux
NCT01281566	Approved	Terminated	Mar 1, 2003	Jul 1, 2003	Infant, Premature

Competing Products

20 competing products in Infant, Premature

See all competitors

Product	Company	Stage	Hype Score
SPIKEVAX	Moderna	Preclinical	0
TSHA-101	Taysha Gene Therapies	Phase 1/2	30
somatropin	Eli Lilly	Phase 3	40
RotaTeq (V260) + IPV	Merck	Phase 3	40
recombinant somatropin	Merck	Pre-clinical	26
Recombinant human growth hormone (r-hGH)	Merck	Phase 3	32
MAS825 + Placebo	Novartis	Phase 2	39
epoetin beta + epoetin beta	Roche	Pre-clinical	26
Genotropin (PN-180,307) Somatropin + Control-no treatment	Pfizer	Phase 3	40
Prevenar (13v)	Pfizer	Pre-clinical	26
rhBSSL + Placebo	Swedish Orphan Biovitrum	Phase 2	35
rhBSSL + Placebo	Swedish Orphan Biovitrum	Phase 2	35
DT5aP-IPV-Hib 5-component Pertussis vaccine + DT3aP-HBs-IPV	Sanofi	Phase 3	40
alglucosidase alfa + alglucosidase alfa	Sanofi	Approved	35
Myozyme	Sanofi	Phase 2	35
Bacillus Clausii Multi ATB Resist + Placebo	Sanofi	Approved	43
Radiprodil	UCB	Phase 2	27
Larotrectinib (Vitrakvi, BAY2757556) + Standard of Care	Bayer	Pre-clinical	23
Sabril®	Lundbeck	Pre-clinical	23
Vigabatrin	Lundbeck	Approved	32